RxDoctor Payments Data

Daniel Sciortino, APRN

Psychiatric/Mental Health · Austintown, OHNPI 1588369821

Payments from drug & device makers

$5,689in general payments, 2019–2025

Across 310 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$695
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$663
  • Teva Pharmaceuticals USA, Inc.$637
  • Otsuka America Pharmaceutical, Inc.$371
  • E.r. Squibb & Sons, L.L.C.$355
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$5,58198%
  • Education$1082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,689 in reported general payments places this provider in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$12,763
Medicare patients
15
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl98$146,189
AustedoDeutetrabenazine12$113,316
AuvelityDextromethorphan Hbr/Bupropion52$57,514
CaplytaLumateperone Tosylate14$26,360
RexultiBrexpiprazole12$17,961
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine108$2,579
Venlafaxine Hcl ErVenlafaxine Hcl61$1,116
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,025
Trazodone Hcl125$721
Hydroxyzine Pamoate68$704
Lurasidone Hcl17$662
Lorazepam85$635
Quetiapine Fumarate41$623
Buspirone Hcl40$576
Diazepam68$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,132$146,18998 claims
Teva Pharmaceuticals USA, Inc.Austedo$637$113,31612 claims
Axsome Therapeutics, Inc.Auvelity$276$57,51452 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$663$26,36014 claims
Otsuka America Pharmaceutical, Inc.Rexulti$371$17,96112 claims
Almatica Pharma LLCSertraline Hcl$99$14445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Austintown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →